Hexagon Bio Raises $61 Million To Advance Novel Small-Molecule Medicines Mined From Microbial Genomes

Sep 22, 2021•almost 4 years ago

Amount Raised

$61 Million

Menlo Park

Description

Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, today announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes. Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.

Company Information

Company

Hexagon Bio

Location

Menlo Park, California, United States

About

Hexagon Bio is a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome. The company’s highly interdisciplinary platform uses data science, genomics, synthetic biology and automation to mine evolutionarily refined small molecules and their protein targets directly from microbial genomes and turn these molecules into therapeutics to combat human diseases that have evaded traditional approaches. Learn more at www.hexagonbio.com or @hexagonbio. *As of the date of this press release, SoftBank Group Corp. has made capital contributions to allow investments by SoftBank Vision Fund 2 ("SVF 2") in certain portfolio companies. The information included herein is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy limited partnership interests in any fund, including SVF 2. SVF 2 has yet to have an external close, and any potential third-party investors shall receive additional information related to any SVF 2 investments prior to closing.

FundzWatch™ Score

Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Funding Insights

Based on industry data

Tech investment trends